Advantages
- New therapeutic target for uterine sarcoma
- Expanding the application of cell cycle-related gene inhibitors to uterine sarcoma
Background
- Uterine sarcoma is a generic term for diseases such as uterine leiomyosarcoma and adenosarcoma, and is a rare cancer with an extremely poor prognosis.
- Existing drugs recently approved for malignant soft tissue tumors (sarcomas and lipomas), such as trabectedin (inhibition of transcriptional function), pazopanib (inhibition of angiogenesis), and eribulin (inhibition of microtubule growth), have been clinically applied to uterine sarcoma, but have not led to dramatic improvement in prognosis.
Current Stage
- We comprehensively analyzed the genes highly expressed in uterine sarcoma and identified a group of cell cycle-related molecules (CDK1, CDK2, CHEK1, CHEK2, Aurora Kinase B, PLK1, and TTK (Mps1)) as new candidate targets for uterine sarcoma.
- We found that several inhibitors of this group of molecules dramatically inhibited the growth of uterine sarcoma cells (100-1000 fold IC50 compared to the aforementioned pazopanib).
- In addition, animal studies confirmed the inhibitory effect of these inhibitors on uterine sarcoma growth. (data not shown)
 |
Principal Investigator
Dr. Akira YOKOI (Tokai National Higher Education and Research System Nagoya University)
Suggestion for Next Step
- We would like to conduct clinical research or investigator-initiated clinical trials in collaboration with pharmaceutical companies/biotech companies.
- We would like to ask for your cooperation in providing us with your inhibitors.
Product No. BK-03896